Search Results for “research” – Page 310 – media

Johnson & Johnson Reports 2017 Second-Quarter Results

New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
- Source: www.jnj.com
- 596
- August 4, 2017
Company Insight
MRC links with UCB in antibody initiative

The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
- Source: pharmatimes
- 855
- August 4, 2017
antibody Company Insight Researches
UK’s University of Bristol develops new test to fight antibiotic resistance

Researchers at the University of Bristol in the UK have developed a new technology to aid general practitioners in prescribing antibiotics and to assist in fighting antibiotic resistance.
- Source: medicaldevices-network.com
- 465
- August 4, 2017
antibiotic resistance Researches
Fast-track pancreatic cancer surgery boosts success, saves money

Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
- Source: pharmatimes
- 410
- August 3, 2017
Clinical Trials NHS pancreatic
UC Riverside tests new biopsy device for cervical cancer

A research team at the University of California, Riverside (UC Riverside) in the US has evaluated a new device manufactured by tissue sampling devices maker Histologics.
- Source: medicaldevices-network.com
- 467
- August 3, 2017
cancer cervical Clinical Trials Researches
Echemi Pharma Forum , A Face-to-Face Meeting in Pharma Asia

Pharma Asia 2017 Pharma Asia is a 3 day event being held from 22nd August to the 24th August 2017 at the Karachi Expo Center in Karachi, Pakistan. This event showcases products like providing investors with a definite outlook of the regional pharmaceutical industry and an opportunity to meet their prospective counterparts and business partners etc. in the Medical & Pharmaceutical industry. Echemi Pharma Forum: From August 22 to 24, Echemi will attend Pharma Asia exhibition, and will take other three Chinese companies to this exhibition. On one side, for visitors, this is a good chance for them to know suppliers and choose their needs directly. On the other side, for suppliers, this is an opportunity to show their products and let more people know their companies. During exhibition period, Echemi will hold “Pharma Forum & Procurement Conference”, which is a face-to-face meeting for suppliers and buyers. There will be ...
- Source: Echemi
- 524
- August 1, 2017
Echemi Exhibitions & Activities ZT League Chemical
Takeda and BioSurfaces to develop new medical devices for GI indications

Japan's Takeda Pharmaceutical Company has signed an agreement with US-based nanotechnology provider BioSurfaces to develop new therapeutic devices to treat gastrointestinal (GI) diseases.
- Source: Medicaldevice-network
- 425
- July 28, 2017
Company Insight gastrointestinal nanofibrous New Approvals
FDA clears BD’s immunological IVD system for commercialization

FDA has granted 510(k) clearance to Becton, Dickinson and Company’s (BD) in-vitro diagnostic (IVD) device, FACSLyric flow cytometer system.
- Source: Medicaldevice-network.com
- 526
- July 27, 2017
Clinical FDA immune New Approvals
NovellusDx to use Gene Editing Institute’s technology for cancer diagnostics

Israel-based NovellusDx has established a genomic cancer research partnership with Christiana Care Health System's Gene Editing Institute to speed-up the development of treatments for the disease.
- Source: Medicaldevice
- 471
- July 24, 2017
cancer Company Insight NovellusDx
Tentative US approval for Merck’s diabetes therapy

The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
- Source: pharmatimes
- 474
- July 21, 2017
Company Insight diabetes Lusduna Nexvue Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.